GRI Bio (NASDAQ: GRI) to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and Hosted by M-Vest
15 juin 2023 08h45 HE
|
GRI Bio, Inc.
- Live webcast fireside chat on Thursday, June 22nd at 12:00 PM ET LA JOLLA, CA, June 15, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company...
GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website
13 juin 2023 08h35 HE
|
GRI Bio, Inc.
Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc....
GRI Bio (NASDAQ: GRI) Provides Business Outlook and Highlights Upcoming Milestones for Innovative Pipeline of NKT Cell Modulators
22 mai 2023 08h45 HE
|
GRI Bio, Inc.
Rapidly advancing clinical pipeline in potential high-value inflammatory, fibrotic and autoimmune diseases Leading NKT regulation technology targeting earlier in the inflammatory cascade to...
GRI Bio (NASDAQ: GRI) to Present at the Virtual Investor New to the Street Event
27 avr. 2023 09h05 HE
|
GRI Bio, Inc.
- Live moderated webcast with members of the GRI Bio management team on Wednesday, May 3rd at 2:00 PM ET LA JOLLA, CA, April 27, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or...
GRI Bio (NASDAQ: GRI) Announces Appointment of Leanne Kelly as Chief Financial Officer
25 avr. 2023 08h45 HE
|
GRI Bio, Inc.
- Financial executive bringing over 20 years of experience in accounting, finance and management with a foundation established from big four accounting firm LA JOLLA, CA, April 25, 2023 (GLOBE...
GRI Bio (NASDAQ: GRI) Announces Board of Director Appointments Adding Leadership and Expertise Spanning a Combined 75 Years in Both Public and Private Sectors in the Life Sciences Industry
24 avr. 2023 08h05 HE
|
GRI Bio, Inc.
LA JOLLA, CA, April 24, 2023 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural Killer T (“NKT”) cell...
Vallon Pharmaceuticals Completes Merger with GRI Bio, Inc.
21 avr. 2023 11h55 HE
|
Vallon Pharmaceuticals Inc.
Combined company will operate as GRI Bio, Inc. and advance innovative pipeline of Natural Killer T (“NKT”) modulating therapies for the treatment of inflammatory, fibrotic and autoimmune...
Vallon Pharmaceuticals Provides an Update on Proxy Voting for the Proposed Merger with GRI Bio and Urges Stockholders of Record as of March 6, 2023 to Vote by April 11, 2023, at 11:59 PM ET
04 avr. 2023 09h00 HE
|
Vallon Pharmaceuticals Inc.
Over 90% of the shares voted to date have shown support “FOR” each of the five proposals, but additional votes are needed in order to close the proposed merger with GRI Bio PHILADELPHIA, PA,...
Vallon Pharmaceuticals Reports Fiscal Year 2022 Financial Results
24 févr. 2023 07h30 HE
|
Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), today reported its financial results for the fiscal year ended December...
Vallon Pharmaceuticals and GRI Bio to Present at the Virtual Investor 2023 Companies to Watch Event
11 janv. 2023 08h45 HE
|
Vallon Pharmaceuticals Inc.
Live video webcast on Tuesday, January 17, 2023 at 1:00 PM ET PHILADELPHIA, PA and LA JOLLA, CA, Jan. 11, 2023 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the...